Resverlogix Corp. · TSX:RVX
Resverlogix — Shareholder Meeting (June 2026)
14 slides from Resverlogix's shareholder meeting presentation, Jun 25, 2026
Slide 1: Annual General Meeting Management Update
1 Annual General Meeting Management Update 2026-06-25
Slide 2: Forward Looking Statement
2 Forward Looking Statement This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends"
Slide 3: Introduction to Resverlogix
3 Introduction to Resverlogix Resverlogix Focus Area: Cardiovascular Disease Founded 2001 Apabetalone works in concert with Standard of Headquarters Calgary, Canada care (SoC) cardiovascular and diabetic drugs (GLP-1 RA, SGLT2i, DPP4i, statins, ACEi, ARBs, insulin, & more) Ownership Publicly-traded
Slide 4: Resverlogix's Lead Candidate – Apabetalone
4 Resverlogix’s Lead Candidate – Apabetalone Orally-available, selective BET inhibitor Priority Indications Well-tolerated – clear safety record with chronic administration Phase Demonstrated cardio-protective benefits – BETonMACE (Phase 3) 3 Heart Failure w/ Diabetes Synergistic benefits in combina
Slide 5: COVID-19: Apabetalone and Disease Progression
5 COVID-19: Apabetalone and Disease Progression Hyper-inflammatory Post COVID-19 Early Infection Pulmonary Phase Phase Conditions Asymptomatic Mild to Moderate Symptoms Severe to Critical Symptoms Ongoing Symptoms (~35%) (~45%) (~20%) (10-50%) Viral Growth and Activity Host Inflammatory Response Poi
Slide 6: COVID-19: Apabetalone and Disease Progression
6 COVID-19: Apabetalone and Disease Progression Hyper-inflammatory Post COVID-19 Early Infection Pulmonary Phase Phase Conditions Asymptomatic Mild to Moderate Symptoms Severe to Critical Symptoms Ongoing Symptoms (~35%) (~45%) (~20%) (10-50%) Apabetalone Limited Viral Growth and Activity Existing T
Slide 7: Post COVID-19 Condition and Prevention of Cardiovascular Outcomes
7 Post COVID-19 Condition and Prevention of Cardiovascular Outcomes Overlap: Increased Burden of Multiple Cardiovascular Events COVID-19 Survivors Non-Infected Control MACE (Major Adverse Cardiac Event) People who contract Heart Attack COVID-19 have a 50%- 70% greater risk of severe cardiac events i
Slide 8: Active Apabetalone Long Covid Study
8 Active Apabetalone Long Covid Study • Recruitment completed • Enrollment target reduced from 200 → 150 Jordan – 2 sites – Examination of baseline data showed statistical power would be met with • Abdali Hospital, Amman reduced enrollment • Istiklal Hospital, Amman – Final enrollment expected to be
Slide 9: Clinical Outcome Measures
9 Clinical Outcome Measures World Health Organization (WHO) – newest standard Patient Acceptable Symptom State Long Covid Impact Tool (PASS) (LCIT) Patients are asked the following: Rate the impact of your illness on: • Personal activities /10 “Taking into account all your symptoms in daily life • F
Slide 10: Biomarker Data - Strong Potential for New Insights
10 Biomarker Data - Strong Potential for New Insights Planned Data Collection Potential Insights Applications Understand Epigenetics of Inflammation Markers Inform Future Trial Design Long-COVID Detail Apabetalone Treatment Bolster Future Submission COVID-19 Markers Responses Datasets Uncover Mechan
Slide 11: Data Safety Monitoring Board Affirms Safety
11 Data Safety Monitoring Board Affirms Safety No cases of patients DSMB convened 3 times to discontinuing study due to Rates of serious adverse review safety data liver function tests and no events (SAE) were lower than Each time agreed to proceed cases of ALT >5x upper limit of in BETonMACE accord
Slide 12: BETonMACE2 Preparations
12 BETonMACE2 Preparations • Detailed trial design discussed with regulators BETonMACE BETonMACE2 (n=2418) (Est. 4500) • Key aspects have been decided – Primary endpoint to include MACE + hospitalizations due to heart failure – Background SGLT2i for all participants – Interim analysis after ~300 eve
Slide 13: Financing Concept – Zenith + Resverlogix
13 Financing Concept – Zenith + Resverlogix Epigenetics Ltd. Zenith (M& A) Zenith Capital Corp. $XXXM $XXXMM M Pharma ~50% ~50% Partner ZCC nt ive ) Righ ince Shareholder t of First Refusal (Extra Dividend • ~50% of the M&A proceeds will be reinvested in apabetalone’s clinical development to fuel lo
Slide 14: Contact
14 Contact Donald McCaffrey | President & CEO 1 403 690 8887 don@resverlogix.com